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ABSTRACT
Introduction: Mexazolam is indicated for the
management of anxiety with or without
psychoneurotic conditions. In adult patients,
the recommended daily dosage of mexazolam is
1–3 mg, administered three times daily. The
objective of this article is to review the available
information on the benzodiazepine (BZD)
mexazolam and its clinical utility in treating
patients with anxiety.
Methods: The PubMed database was searched
using the keyword ‘‘mexazolam’’ with no date or
language restrictions applied to the search. As
only 11 papers were retrieved, some previously
published manuscripts of interest known by the
authors (not indexed on PubMed) have been
added for completeness. Relevant information
was selected for inclusion by the authors.
Results: A number of early studies
demonstrated the ability of mexazolam to
reduce anxiety symptoms with few side effects
in patients with disorders associated with
anxiety. Following on from this preliminary
evidence, controlled studies directly comparing
mexazolam with other BZDs showed that the
drug is more effective than bromazepam and
oxazolam, and is at least as effective as
alprazolam. A larger, multicenter, phase IV
study also showed that mexazolam 2 or 3 mg/
day rapidly improved Hamilton Anxiety Rating
Scale scores and substantially reduced the
frequency and severity of numerous somatic
anxiety symptoms in patients with anxiety
disorders. With regard to safety, the clinical
evidence indicates that mexazolam is generally
well tolerated, with a low incidence of
drowsiness and sedation. Furthermore, the
lack of psychomotor or cognitive performance
impairment following mexazolam
administration may lead to better treatment
compliance.
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Conclusion: The available clinical evidence
suggests that mexazolam is an effective
therapeutic option for the management of
anxiety. However, larger, well-controlled
clinical trials are needed to directly compare
and contrast mexazolam’s efficacy and safety
with other BZDs.
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INTRODUCTION
Epidemiological research has indicated that
anxiety disorders are among the most
common psychiatric disorders in the United
States [1–3]. Furthermore, data from a World
Health Organization World Mental Health
survey reported anxiety disorders to be the
most common mental disorder (estimated
lifetime prevalence of 4.8–31.0%) in numerous
countries across Africa, Asia, the Americas,
Europe, and the Middle East [4].
The most commonly occurring anxiety
disorders include generalized anxiety disorder,
panic attacks, panic disorder, specific phobia,
social anxiety disorder, agoraphobia, trauma-
and stressor-related disorders, obsessive–
compulsive and related disorders, separation
anxiety disorder, and illness anxiety disorder
[5]. These disorders are marked by excessive
fear, anxiety, and associated avoidance
behaviors, but are distinguished from each
other by the types of objects or situations that
induce the fear or avoidance. Anxiety disorders
are marked by persistence, rather than transient
fear or anxiety, and tend to have their onset in
childhood or adolescence (Diagnostic and
Statistical Manual of Mental Disorders
[DSM]-5) [5].
Following an accurate diagnosis, the
recommended treatment options for anxiety
disorders include psychotherapies and
pharmacological therapies [6–8].
Benzodiazepines (BZDs) are a class of drugs
that bind to specific BZD-type receptors on the
gamma-aminobutyric acid (GABA) chloride ion
complex and facilitate GABA inhibitory effects
[9, 10]. Although BZDs are not generally
recommended for first-line, long-term
management of anxiety disorders in clinical
practice, their use as second-line treatment is
widespread [11].
In 1956, Dr. Leo Sternbach discovered the
first BZD, chlordiazepoxide (approved in 1960),
which was followed by the release of its
congener, diazepam, in 1963 [11]. Since the
release of chlordiazepoxide and diazepam, more
than 1,000 BZDs have been synthesized. [11].
More recently, four non-BZD hypnotics
(zaleplon, zolpidem, zopiclone, and
eszopiclone), also known as the so-called
z-drugs, were introduced. Although these
compounds are effective for the initial
treatment of insomnia, their clinical effects are
not sustained through the night [11].
Today, there are a wide range of BZDs
available for use in clinical practice. Despite
sharing the same mechanism of action, they
vary in their duration of action (short- vs. long-
acting) and difference in pharmacokinetic
profiles translate, in clinical practice, into
differences in their main therapeutic effect
(anxiolytic vs. hypnotic) [11, 12]. BZDs with a
strong anxiolytic effect at therapeutic doses,
such as diazepam, are effective for the relief of
anxiety states, while BZDs with a predominant
hypnotic effect, such as flurazepam, are used for
the short-term treatment of insomnia [11].
BZDs such as clonazepam are also associated
with anticonvulsant effects [13].
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In addition to their clinical effectiveness,
one of the main advantages of BZDs in the
treatment of anxiety is their early onset of
action [14], which may explain why these
agents continue to be widely prescribed.
However, BZDs may be associated with a
number of adverse effects, particularly at
higher doses, which include sedation, physical
and psychic dependence, and impaired
concentration, memory and psychomotor
performance [14]. Furthermore, withdrawal
symptoms and rebound anxiety may be
associated with the long-term use of these
agents [14]. The frequency and severity of
these adverse events may also vary between
BZDs. BZDs have also been linked to substance
abuse/misuse and dependence when used long-
term [15].
With the current availability of a variety of
BZDs, clinicians are frequently faced with
difficulties in choosing the most appropriate
BZD for an individual patient. Therefore, it is
important for clinicians to have a good
understanding of the main characteristics and
differences of these drugs. The BZD mexazolam,
although currently used in the treatment of
anxiety disorders, is not well known and clinical
publications are limited and so, in this context,
the objective of this article is to review the
available information on mexazolam and its
clinical utility in treating patients with anxiety.
METHODS
The PubMed database was searched for articles
using the keyword ‘‘mexazolam’’. Only 11
results were retrieved. In order to ensure the
review article was as comprehensive as possible,
some previously published manuscripts of
interest known by the authors have been
added. Subsequently, the authors have selected
the most relevant information (all preclinical
and clinical data, determinant to the
interpretation of the several characteristics of
mexazolam discussed in the article, were
considered to be relevant information by the
authors). No date or language restrictions were
applied to the search.
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
MEXAZOLAM
Mexazolam (also known as CS-386) is currently
indicated for the management of anxiety with
or without psychoneurotic conditions when the
disorder is severe, disabling, or subjecting the
individual to extreme distress [16]. The duration
of treatment should be as short as possible and
the dosage of mexazolam should be adjusted
based on an individual patient’s age and the
severity of symptoms. In adults, the average
daily dose is 1–3 mg, which is preferably
administered three times daily (TID); the daily
dosage should not exceed 1.5 mg in elderly





d] [1, 4] diazepin-6(5H)-one) is an anxiolytic
oxazolo-BZD that is structurally similar to
oxazolam and cloxazolam [17].
Pharmacokinetic Considerations
After the oral administration of mexazolam, its
active metabolites chloronordiazepam (CND)
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and chloroxazepam (COX), but not the
unaltered drug, are detected in the blood.
Mexazolam appears to be hydroxylated and
conjugated in the liver through two different
metabolic pathways (BZD-type [active
metabolites] and benzophenone-type [inactive
metabolites]) [16]. The time-to-peak plasma
concentration for CND is 1–2 h following
the administration of a single oral dose
of mexazolam. A bi-compartmental
pharmacokinetic model can be applied, with a
biphasic plasma concentration curve, and first
and second half-lives of 1.4 and 76 h,
respectively. Both CND and COX are mainly
bound to plasma proteins ([90%), and the
majority of the drug is excreted via bile (\10%
of an oral dose of mexazolam is eliminated as
metabolites in urine) [16, 18]. The active
metabolite, COX, represents more than 50% of
the total amount of excreted metabolites, and is
essentially found as a conjugate [16, 19].
Although only small amounts of mexazolam
may be found in breast milk, the drug should
not be given to breast feeding mothers [16, 19].
Preclinical Studies
Like cloxazolam and oxazolam, mexazolam
demonstrated a broad safety profile and very
low acute toxicity in preclinical studies. The
results of studies conducted in rats reported that
the subacute or chronic administration of
mexazolam showed no toxic reactions below a
dosage of 125 mg/kg [16, 20]. Teratogenicity
and mutagenic tests were negative, and
preclinical animal studies did not indicate any
harmful effects for mexazolam during
pregnancy [16, 17]. However, the safety of this
drug in humans has not been established during
pregnancy.
Preclinical studies showed that mexazolam
was 2–3 times more effective than diazepam
and cloxazolam at improving performance in
conflict behavior or lever-pressing tests
(regarded as a measure of an antianxiety
effect) [21, 22]. Mexazolam was also shown to
inhibit megimide-induced convulsions in mice
[23]. In electrophysiological tests using cats,
mexazolam showed a stronger action than
those of cloxazolam and diazepam with
respect to the cerebral marginal gyrus,
especially the amygdaloid nucleus, which
plays important roles in instinctive behavior
and emotional activity. Concomitant side
effects such as drowsiness, muscle relaxation,
and motor ataxia are weaker than those of
diazepam and cloxazolam [23]. The results of
preclinical studies also showed that mexazolam
appears to have a more potent antianxiety effect
than cloxazolam and diazepam, while causing
less muscular relaxation, sedation, and ataxia
[23, 24].
Clinical Studies
Mexazolam has been extensively studied for the
treatment of anxiety disorders, and the results
of a number of clinical trials have been
published. Phase I and II trials reported that
mexazolam was associated with a reduction in
anxiety symptoms and few side effects [25–30].
A phase III, multicenter, double-blind,
randomized study of 165 patients with
psychosomatic disorders or neurosis confirmed
the antianxiety effect of mexazolam (final
global improvement rates of 75.6% and 63.8%
with mexazolam and oxazolam, respectively)
[31]. Based on these results, the authors
concluded that mexazolam appeared to be a
more effective drug than oxazolam.
A number of additional studies have since
been conducted to determine the clinical
efficacy and tolerability of mexazolam.
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Clinical Efficacy
Katsunuma et al. [23] conducted a phase II
open-label uncontrolled study in an adult/
elderly population of 29 patients (age range
44–91 years) diagnosed with neurosis, anxiety,
insomnia, indefinite complaints, and
psychosomatic diseases from the Geriatric
Department of Tokyo Medical College
Hospital. It should be noted that the dosing
schedule for mexazolam was different in this
study compared with the currently approved
dosing schedule [16]. Initially, mexazolam was
administered at a dose of 1 mg TID, followed by
uptitration to 2 mg TID according to
conditions. According to the evaluation of
treatment effectiveness (excellent, good, fair,
and poor), 15 of 29 patients (51.7%) classified
their treatment as excellent, 9 patients (31.0%)
considered their treatment to be good, and 5
patients (17.2%) considered it to be fair. The
overall efficacy rate (proportion of patients with
a treatment effectiveness of excellent or good)
was 82.7%, and efficacy rates between younger
(aged B59 years) and elderly (C60 years)
patients were similar (85.7% vs. 81.8%) [23].
Ohara et al. [32] conducted a prospective,
multicenter open-label, uncontrolled study in
44 Japanese patients (21 males and 23 females)
with diseases that fell under the category of
‘‘neurosis’’. Patients were initially treated with
mexazolam at a daily dosage of 1 mg, which
could be adjusted, as required, based on the
condition of the disease. The Hamilton Anxiety
Rating Scale (HAM-A), and final global
improvement rates (assessment of efficacy)
were evaluated at baseline and weekly
intervals until the end of the treatment period
(4 weeks). Final global improvement rates were
‘‘markedly improved’’ in 15 patients (34.1%),
‘‘improved’’ in 14 patients (31.8%), ‘‘slightly
improved’’ in 10 patients (22.7%), and were
rated as ‘‘no change’’ in 4 patients (9.1%).
Mexazolam rapidly improved the mean HAM-
A score by reducing it from 22.0 points at
baseline to 14.5 points at Week 1, 10.0 points at
Week 2, 9.0 points at Week 3, and 7.0 points at
Week 4. One patient dropped out of the study
due to a diagnosis of hysteria [32].
Vaz-Serra [33] conducted a 4-week double-
blind study that compared the efficacy and
safety of mexazolam [1 mg twice daily (BID)]
and bromazepam (3 mg BID) in 60 patients.
Efficacy was assessed at 0, 14, and 28 days using
the HAM-A scale and investigator-reported
global clinical evaluation of the patient.
Significant reductions in HAM-A scores were
seen in both treatment groups at Days 14 and
28 (Fig. 1). Furthermore, the reductions were
greater in patients treated with mexazolam.
These results appeared to translate to an
overall improvement in patient functioning
for both study drugs, although this
improvement was statistically higher with
mexazolam [33].
Fig. 1 Mean Hamilton Anxiety Rating Scale (HAM-A)
scores at Days 0, 14, and 28 during treatment with
mexazolam or bromazepam. Lambda de Wilks = 0.478,
F test = 25.107; P = 0.000. Adapted with permission
from Vaz-Serra A. Estudo clı´nico com dupla ocultaça˜o
comparando mexazolam com bromazepam. Psiquiatrı´a
clı´nica. 1993;14(2):77–84
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In addition to the assessment of HAM-A, the
investigator-reported global clinical evaluation
of the patients at Day 14 showed that 16 of the
25 patients (64.0%) treated with mexazolam
had a significant improvement, compared with
8 of the 24 patients (33.3%) treated with
bromazepam [33]. At study end (Day 28), the
majority of patients treated with mexazolam
(92.0%) showed a significant improvement,
compared with 58.3% of patients treated with
bromazepam.
Vieira Coelho and Garrett [17] published a
prospective, multicenter, open-label,
uncontrolled phase IV study that was
conducted in the psychiatry departments of
nine Portuguese hospitals. A total of 409
patients (aged 18–60 years) with a diagnosis of
anxiety disorder (according to DSM-III-R
classification) were enrolled; the majority of
these patients had generalized anxiety disorder.
Patients received mexazolam 2 or 3 mg/day
(according to their baseline HAM-A score) for
28 days, and clinical observations were recorded
on Days 0, 7, and 28. Efficacy was evaluated by
the HAM-A scale and a list of 27 symptoms was
used to assess the frequency and severity of
somatic anxiety components. Mexazolam
significantly reduced mean (±SD) HAM-A
scores from 28.1 ± 0.38 at baseline, to
19.6 ± 0.39 at Day 7, and 12.1 ± 0.4 at Day 28
(both P\0.05 vs. baseline) [17]. Mexazolam
also reduced the 27 somatic anxiety symptoms
that were evaluated. Greater percent reductions
in frequency and severity were noted for
asthenia, headache, distractedness, irritability,
restlessness, palpitations, and chest tightness
(Table 1). At study end, the improvement in
symptoms was considered to be ‘‘excellent’’ or
‘‘very good’’ in 65% of patients, ‘‘fair’’ in 24%,
and ‘‘null’’ in 11% [17].
Vaz-Serra et al. [34] compared the anxiolytic
effects of mexazolam and alprazolam in
patients with generalized anxiety disorder
(DSM-IV criteria). This 5-week multicenter,
double-blind, randomized, parallel-group trial
randomly assigned 64 patients to fixed doses of
mexazolam 1 mg TID or alprazolam 0.5 mg TID
for 1 week, followed by a 2-week period where
the dosages of both drugs could be reduced
according to therapeutic response. On Day 21, a
1-week taper period was initiated, which was
followed by a 1-week treatment-free follow-up
period. The two main measures of efficacy were
the assessment of the HAM-A and Clinical
Global Impression (CGI) scales, which were
evaluated at baseline (Day 0), Day 7, Day 21,
Day 28, and Day 35. A significant anxiolytic
Table 1 Percentage reductions in the frequency and
severity of somatic anxiety symptoms after 28 days of
treatment with mexazolam in patients with anxiety
disorders. Reproduced with permission from Vieira
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effect was seen in both treatment groups at
study end, as seen by a significant reduction
from baseline in the mean HAM-A score of
16.28 with mexazolam (P\0.0001 vs. baseline)
and 14.2 with alprazolam (P\0.0001 vs.
baseline; Fig. 2) [34]. On Day 7, the proportion
of HAM-A responders (a decrease from baseline
in HAM-A global scores of C50%) was 35.5%
with mexazolam and 23.3% with alprazolam;
HAM-A responder rates were further increased
to 80.0% with mexazolam and 70.0% with
alprazolam on Day 21 [34]. Although these
results appeared to be higher in the mexazolam
group, the between-group differences between
mexazolam and alprazolam were not
statistically significant. Mexazolam and
alprazolam were also associated with
significant mean reductions from baseline in
the mean CGI-disease severity score (CGI-DSS;
2.66 and 2.44, respectively; both P\0.0001 vs.
baseline), with no significant between-group
differences [34]. Furthermore, the beneficial
anxiolytic effects of mexazolam and
alprazolam were sustained during the tapering
and withdrawal periods, as shown by the CGI-
DSS mean scores remaining significantly lower
than baseline in both treatment groups. As with
the HAM-A score, CGI-global improvement
score (CGI-GIS) responder rates (the
proportion of patients who were ‘‘highly
improved’’ or ‘‘moderately improved’’) were
higher in the mexazolam group compared
with the alprazolam group at the end of weeks
1 (54.8% vs. 46.7%) and 3 (96.7% vs. 86.7%);
however, these differences did not reach
statistical significance [34].
Clinical Tolerability
With regard to tolerability, Katsunuma et al.
[23] reported a mild degree of drowsiness in 5 of
the 29 patients (17.2%). In addition, no falls
were reported.
In the study conducted by Ohara et al. [32],
mexazolam-related side effects were reported in
11 of the 44 patients (25.0%); drowsiness was
the most frequently reported side effect (7
patients). No serious side effects requiring a
reduction in dosage were reported [32]. In
addition, no abnormalities in clinical
laboratory tests (including hematological and
urinalysis findings) were seen in the 24 patients
who underwent testing before and after the
completion of mexazolam therapy.
In the study published by Vaz-Serra [33] in
1993, no side effects were reported in the
majority of patients; side effects were generally
minor in terms of severity, and did not alter the
general state of the patient. In a clinical
assessment of general symptoms that could be
considered to be side effects, no significant
changes in these symptoms were seen prior to
versus during mexazolam therapy. Asthenia and
sedation were the symptoms most frequently
reported during the study. Vaz-Serra [33] also
assessed memory changes, which are often
Fig. 2 Changes from baseline in the Hamilton Anxiety
Rating Scale (HAM-A) mean score during treatment with
mexazolam or alprazolam in patients with generalized
anxiety disorder (within-group analysis: P\0.0001, Fried-
man non-parametric test; between-group comparison:
P[0.05, analysis of variance). Adapted with permission
from Vaz-Serra A et al. [33]
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adversely affected by the use of BZDs. Memory
changes were evaluated using the digit span test
(the ability of a patient to fix and immediately
reproduce a sequence of five numbers, repeating
this procedure three times in each observation)
and a questionnaire to evaluate memory
retention and recall [33]. The results showed
no detrimental alterations in patient memory;
in fact, a significant improvement in the digit
span test was seen for mexazolam versus
bromazepam (P = 0.015). This finding suggests
that the improvement in anxiety levels may
lead to improvements in the capacity to retain
and subsequently recall messages.
In the phase IV study conducted by Vieira
Coelho and Garrett [17], the overall incidence
of side effects was 11.7% at Day 28, with the
most frequent event being daytime sedation
(7.5% of patients). The investigator-rated
intensity of side effects was considered to be
inconsequential in 65% of patients and mild in
31%; side effects that interfered with normal
daily activity were reported in 4% of patients.
The effect of mexazolam on cognition and
memory performance was evaluated by an
objective test [Negative Symptom Rating Scale:
B-cognition III x-Memory (NSRS)], which
showed no impairment of cognitive function
during the study. Similar to the Vaz-Serra [33]
1993 study, enhanced performance on the
memory test, demonstrated by significant
improvements from Day 0 in NSRS scores at
Days 7 and 28 (both P\0.05) was observed in
patients receiving mexazolam and authors
again indicated that memory improvement
was likely to be related to the anxiolytic effect
of mexazolam (Fig. 3) [17].
In 2001, the study by Vaz-Serra et al. [34]
reported no clinically important differences
in tolerability between mexazolam and
alprazolam. Adverse events in both treatment
groups were mild to moderate in intensity and
consistent with the well-known tolerability
profile of BZDs. The most commonly reported
event was drowsiness, which occurred in 9.7%
and 10.0% of patients receiving mexazolam and
alprazolam, respectively.
In addition to the safety issues described
above, BZD use has been associated with
impaired psychomotor function, resulting in
the disruption of tasks that require sustained
attention, vigilance, speed, and accuracy [35–
37]. Preclinical studies indicate that although
the anxiolytic properties of mexazolam are
similar to those of diazepam and cloxazepam,
mexazolam produces less sedation, ataxia, and
muscular relaxation [38]. This suggests that
mexazolam may be associated with fewer
deleterious effects on psychomotor
performance and cognitive function than
other BZDs. It was in this context that Silveira
et al. [18] conducted a double-blind,
randomized, two-way crossover, placebo-
controlled study in 33 healthy adult
volunteers to assess the effect of a single 1-mg
oral dose of mexazolam on psychomotor
performance. Psychomotor performance was
Fig. 3 Mean scores on the Negative Symptom Rating
Scales: B-Cognition III (x-Memory) (NSRS). Word recall
was assessed as follows: a all ﬁve words recalled without
difﬁculty (rating of 0); b four words or possible recall of ﬁfth
word after prompting (-1 to -2); c two or three words
recalled, prompting notwithstanding (-3 to -4); d no
words recalled or possible recall of one word after prompting
(-5 to -6).*P\0.05 (Wilcoxon test); signiﬁcance
between consecutive evaluations. Adapted with permission
from Vieira Coelho and Garrett [17]
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evaluated using the Leeds Psychomotor Test
(LPT) Battery [comprising the critical flicker
fusion (CFF) threshold evaluating visual
information processing time and the choice
reaction time with its three components—
recognition reaction time (RRT), motor
reaction time (MRT), and total reaction time
(TRT)] and a car-driving simulation (CDS). After
the administration of mexazolam, changes (pre-
vs. 3 h post-administration) in the LPT Battery
and CDS results were not significantly different
compared with placebo (Table 2) [18]. CDS
results indicated a significant improvement for
both placebo and mexazolam, which indicated
a learning effect induced by repetition of the
tests (Table 2). Regarding adverse events, three
subjects reported three events, one
(somnolence) in the mexazolam group.
Ferreira et al. [24] conducted a multicenter,
randomized, double-blind, parallel-group,
placebo-controlled clinical trial in 60
outpatients with generalized anxiety disorder
(DSM-IV criteria) who received treatment with
mexazolam 1 mg TID (n = 32) or placebo
(n = 28) for 21 days (Visit 1, screening and
start of placebo run-in; Visit 2, Day 0; Visit 3,
Day 7; Visit 4, Day 21). The effects of
mexazolam on psychomotor performance (as
assessed by the LPT Battery; primary endpoint)
and clinical status (HAM-A and CGI) were
evaluated.
No statistically significant differences were
seen between mexazolam and placebo with
regard to the LPT Battery results (CFF, RRT,
MRT, and TRT) [24]. Regarding HAM-A
assessment, significant improvements in total
and somatic scores were seen with mexazolam
versus placebo at Day 7, but not at Day 21.
However, it should be noted that sample size
was estimated on the basis of the CFF
parameter, and that high-dose regimens of
well-established drugs such as diazepam have
also shown this phenomenon. The most
frequently reported adverse event was
Table 2 Leeds Psychomotor Test Battery (critical ﬂicker fusion threshold; motor reaction time; recognition reaction time;
total reaction time) and car-driving simulation (total time score; best lap time) results before and after a single oral dose of
mexazolam 1 mg or placebo in healthy volunteers
Placebo Mexazolam
Pre-dose Post-dose Pre-dose Post-dose
Leeds Psychomotor Test Battery results
CFF threshold (Hz) 29.03 ± 2.94 29.06 ± 3.01 29.62 ± 3.01 28.85 ± 3.35
RRT (ms) 379.74 ± 44.29 385.87 ± 39.59 381.18 ± 56.64 378.42 ± 36.66
MRT (ms) 209.25 ± 39.92 208.77 ± 43.90 210.35 ± 37.24 205.05 ± 33.58
TRT (ms) 588.99 ± 67.00 594.64 ± 63.22 591.52 ± 74.58 583.47 ± 51.37
Car-driving simulation results
TTS (s) 745.69 ± 208.70 708.61 ± 125.45* 724.70 ± 90.73 707.19 ± 75.15*
BLT (s) 44.73 ± 9.81 43.02 ± 6.07* 43.69 ± 4.12 43.02 ± 3.19*
Data shown are mean ± SD. Data from Silveira et al. [18]
BLT best lap time, CFF critical ﬂicker fusion, Hz Hertz, MRT motor reaction time, ms millisecond, RRT recognition
reaction time; s second, TRT total reaction time
* P\0.05 versus pre-dose values
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drowsiness, which occurred in eight patients
receiving mexazolam and one patient receiving
placebo.
DISCUSSION
To our knowledge this is the first review of
articles to be conducted for mexazolam. Despite
the wide availability of BZDs and their
rapid onset of action, selective serotonin
reuptake inhibitors (SSRIs) and serotonin–
norepinephrine reuptake inhibitors (SNRIs) are
the recommended first-line agents for anxiety
due to their favorable risk–benefit ratio, with
BZDs used as an adjunct to SSRIs and SNRIs in
the first few weeks of treatment (for control of
short-term anxiety or when deemed necessary
by the clinician [6]. BZDs can be a useful
adjunct, as the anxiolytic effect of SSRIs and
SNRIs has a delayed onset of action of
2–4 weeks, and, in some cases, up to
6–8 weeks); however, we have not found in
the literature any papers describing or
evaluating this specific use of mexazolam in
the short-term treatment of anxiety.
Globally, BZDs have a good safety record and
should be used with a regular dosing regimen
but are not effective in acute stress disorder, in
patients with comorbid depression, or in those
with obsessive–compulsive and related
disorders [6].
Mexazolam is not mentioned specifically in
the latest European guidelines, probably
because it is not available in many European
countries (nevertheless, it is mentioned in
national guidelines of countries where the
drug is available, for example, Portugal) [39].
Mexazolam is approved in some other countries
in Europe, Central America, Africa, and Asia. In
this sense, it has become important to conduct
a review of the clinical characteristics of
mexazolam.
In our research for this manuscript, we found
a lack of recent clinical data on mexazolam, and
that is the main limitation of this review. This
lack of recent clinical data is probably due to the
fact that mexazolam has had an established
therapeutic value in the management of anxiety
for many years, with no expected potential use
in other indications, and thus no further
clinical trials have been conducted.
Nevertheless, the clinical use of mexazolam
and BZDs in general is valuable; mexazolam
has been shown to be useful in the management
of anxiety with or without psychoneurotic
conditions when the disorder is severe,
disabling, or subjecting the individual to
extreme distress [17].
The efficacy and tolerability of mexazolam in
patients (including the elderly) with disorders
associated with anxiety appears to have been
previously well established based on the clinical
data that is available in the literature [24, 26,
31–33]. Following on from this initial evidence,
a number of additional multicenter and
comparative phase III/IV clinical trials have
been subsequently conducted to confirm the
efficacy and safety of mexazolam for this
indication [17, 18, 24, 31–34, 40–46].
The multicenter, phase IV trial by Vieira
Coelho and Garrett [17] confirmed the efficacy
of mexazolam in the treatment of anxiety,
demonstrating a rapid anxiolytic effect that
resulted in a 30% reduction in HAM-A scores
after 1 week of treatment; further reductions
were seen at Day 28. Somatic symptoms
commonly associated with anxiety were also
reduced by approximately 80–94% following
treatment with mexazolam [17]. Based on these
findings, the authors concluded that
mexazolam was an effective anxiolytic with a
good safety profile (no impairment of cognitive
function or major sedative side effects was
reported).
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Two comparative studies [33, 34] were
conducted after the publication of an initial
comparative study of mexazolam versus
oxazolam by Suzuki et al. [31] in 1980. In
1993, Vaz-Serra [33] concluded that mexazolam
provided a superior anxiolytic effect versus
bromazepam. With regard to tolerability, no
significant treatment-related side effects were
seen with either study drug, particularly
detrimental changes in memory/cognition (a
finding that was later reinforced by Vieira
Coelho and Garrett [17]).
A second comparative study was conducted
by Vaz-Serra et al. [34] in 2001, which
concluded that both mexazolam and
alprazolam were well tolerated. Daytime
sedation was the most frequently reported side
effect (9.7% of patients) associated with the use
of mexazolam. The frequency of daytime
sedation in the mexazolam group for this
study was similar to that observed in Vieira
Coelho and Garrett [17] (7.5%), and lower than
that observed in the studies by Katsunuma et al.
[23] and Ohara et al. [32] (although the
mexazolam dosages used in these two studies
were higher [6 and 4 mg/day, respectively] and
they were not double-blind, placebo-controlled
studies). With regard to efficacy, Vaz-Serra et al.
[34] concluded that mexazolam appeared to be
associated with higher HAM-A and CGI-GIS
responder rates versus alprazolam, although the
between-group differences did not reach
statistical significance. The study also showed
that mexazolam had a fast onset of action
(significant reductions in anxiety scores were
seen in the first week of treatment) and a
sustained effect throughout the study,
including the tapering and treatment-free
follow-up periods [34]. This short latency of
the anxiolytic effect for mexazolam is clinically
relevant, because it enables the rapid and
consistent control of symptoms.
The impairment of psychomotor
performance and cognitive performance are
two major complaints associated with BZD
therapy, particularly during long-term use [40–
43]. In the study by Silveira et al. [18], LPT
Battery and CDS results revealed no statistically
significant differences between mexazolam and
placebo. These findings are in accordance with
the good tolerability profile of mexazolam in
previously reported clinical trials, particularly
the low incidence of drowsiness and sedation
[34]. The results of this study are of clinical
relevance because there was an absence of
adverse psychomotor effects at the time when
such effects are most likely to occur during
treatment with mexazolam or other BZDs. In
contrast to mexazolam, significant reductions
in speed of visual information processing
(measured by CFF threshold) have been seen
with other BZDs (diazepam, chlordiazepoxide,
oxazepam, lorazepam, and nitrazepam) [44, 45],
which indicates a negative effect on overall
central nervous system activity. The use of these
BZDs as antianxiety treatments has also been
associated with side effects such as
forgetfulness, impairment of psychomotor
function, fatigue, and reductions in attention,
cognitive ability, and overall psychological
skills. Based on the results reported by Silveira
et al. [18] and the fact that mexazolam 1 mg is
equivalent to diazepam 1 mg [46], it is possible
that mexazolam therapy may be associated with
few adverse effects on cognitive function and
little or no impairment of daily activities.
Furthermore, Silveira et al. [18] showed that
mexazolam did not affect learning ability (no
significant differences compared with placebo).
Finally, the study by Ferreira et al. [24]
showed that there was an absence of
disruptive effects on psychomotor
performance following the administration of
clinically effective anxiolytic dosages of
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mexazolam. Mexazolam demonstrated a good
tolerability profile in this study, which was in
agreement with the absence of psychomotor
and cognitive performance impairment; this in
turn may lead to better compliance. However,
the small sample size of the study does not
allow accurate conclusions to be drawn.
Although the clinical evidence is limited, it
would appear that mexazolam is at least as
effective (e.g., alprazolam) or even more effective
(e.g., bromazepam and oxazolam) than other
BZDs and better tolerated and so it may have the
potential for an increased role in the treatment of
anxiety and other specific indications.
Other considerations for use of mexazolam
over other BZDs and other treatment used in
the management of anxiety include its relative
cost effectiveness. Currently, there are no
pharmacoeconomic data for mexazolam. Until
such data are available, one can substantiate its
clinical use by other important parameters such
as clinical efficacy and tolerability.
CONCLUSION
To our knowledge, this is the first published
review article that provides an overview on the
use of mexazolam in the treatment of anxiety.
Mexazolam is indicated for the management of
anxiety with or without psychoneurotic
conditions. In addition to its clinical efficacy,
mexazolam is also associated with a rapid onset
of its anxiolytic effect. The limited clinical
evidence that is available to date suggests that
mexazolam is more effective than bromazepam
and oxazolam, and is at least as effective as
alprazolam. Furthermore, mexazolam does not
appear to be associated with adverse effects on
the psychomotor and cognitive performance of
anxious patients, which may lead to better
compliance and additional specific indications
for this drug. Additional, larger, well-controlled
studies are required to further establish and
directly compare mexazolam’s efficacy and
tolerability with other BZDs for the
management of anxiety.
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